Long-term treatment (36 h) of cells with atherogenic cholesterol destabilized IP3R1, which typically decreases in chronic atherosclerosis; however, MG132 treatment reverses this decrease suggesting this receptor is targeted for degradation in atherosclerosis (Fig. 1g, h)28,29. The gene discussed is ITPR1; the disease is atherosclerosis.